Barclays Sticks to Its Hold Rating for Exelixis (EXEL)
Barclays analyst Etzer Darout maintained a Hold rating on Exelixis today and set a price target of $44.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Darout is a 5-star analyst with an average return of 24.1% and a 55.13% success rate. Darout covers the Healthcare sector, focusing on stocks such as Kura Oncology, Syndax Pharmaceuticals, and Exelixis.
In addition to Barclays, Exelixis also received a Hold from Morgan Stanley’s Sean Laaman in a report issued on February 2. However, yesterday, H.C. Wainwright reiterated a Buy rating on Exelixis (NASDAQ: EXEL).
Based on Exelixis’ latest earnings release for the quarter ending October 3, the company reported a quarterly revenue of $597.76 million and a net profit of $193.58 million. In comparison, last year the company earned a revenue of $539.54 million and had a net profit of $117.97 million
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Most recently, in November 2025, DAVID EDWARD JOHNSON, a Director at EXEL bought 27,532.00 shares for a total of $1,187,179.84.
Read More on EXEL:
Disclaimer & DisclosureReport an Issue
- Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
- Exelixis reports zanzalintinib new drug application accepted for review by FDA
- Exelixis price target raised to $49 from $48 at Morgan Stanley
- Exelixis price target raised to $52 from $49 at H.C. Wainwright
- Exelixis price target raised to $51 from $49 at Truist
